title: [Respiratory infections and inhalation insulin therapy].
abstract: A very important change in diabetology will come soon--introduction of inhalation insulin to the market. Experiences with this therapy are now more than 4 years long and no severe complications are present. Respiratory infections are not more frequent and it is not necessary to change insulin dosing during these infections. Insulin is more absorbed in smokers. The research of inhalation insulin brought again attention to diabetic pneumopathy. This disease has no clinical importance as has no relation to inhalation insulin therapy.
authors.affiliation: III. interní klinika 1. lékarské fakulty UK a VFN, Praha. svacinas@lf1.cuni.cz
authors.forename: S
authors.initials: S
authors.lastname: Svacina
mesh_terms: D000280:Administration, Inhalation; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D012141:Respiratory Tract Infections / Q000150:complications / Q000503:physiopathology*
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin